CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 36 enrolled
Drug / intervention
Lasmiditan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03406260
NCT03406260Phase 1Completed
CompareCT.gov

A Study to Investigate the Cardiovascular Effects of Lasmiditan in Healthy Elderly Subjects

Eli Lilly and Company·interventional·Posted Jan 23, 2018·Updated Dec 2, 2019

In Brief

A Phase 1 clinical trial evaluating Lasmiditan and Placebo for Healthy. Completed, enrolled 36 participants across 2 sites.

Detailed Summary

The purposes of this study are to evaluate the effect of lasmiditan on blood pressure, as well as to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it in healthy elderly participants. The tolerability of the study drug will also be evaluated. Information about any side effects that may occur will also be collected. This study will take about 11 days, not including screening. Screening is required within 28 days prior to the start of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJan 23, 2018
Enrollment StartJan 25, 2018
Primary CompletionApr 13, 2018
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.4 years ago

Interventions

Lasmiditandrug

Administered orally.

Placebodrug

Administered orally.